



23 Julai 2019  
23 July 2019  
P.U. (A) 202

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)  
(NO. 2) 2019

*POISONS (AMENDMENT OF POISONS LIST)  
(NO. 2) ORDER 2019*

DISIARKAN OLEH/  
*PUBLISHED BY*  
JABATAN PEGUAM NEGARA/  
*ATTORNEY GENERAL'S CHAMBERS*

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2019

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 2) 2019**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dalam senarai “Antihistamines; the following:”, dengan memasukkan selepas butiran “Doxylamine” butiran “Ebastine”;
- (ii) dengan memasukkan selepas butiran “Bretylum; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
"Brexpiprazole	-	All preparations";					

- (iii) dengan memasukkan selepas butiran "Chlorzoxazone" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Cholecalciferol	-	All medicinal preparations containing 10,000 i.u. or more of cholecalciferol per dosage unit	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B or Group C";

- (iv) dengan memasukkan selepas butiran “Duloxetine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dupilumab	-	All preparations				
Durvalumab	-	All preparations”;				

- (v) dengan menggantikan butiran “3,4-Methylenedioxy-methamphetamine (MDMA)(DD)” dengan butiran “3,4-Methylenedioxymethamphetamine (MDMA)(DD)”;

- (vi) dengan memasukkan selepas butiran “Pomalidomide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ponatinib	-	All preparations”;				

(vii) dengan memasukkan selepas butiran “Santonin” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Sapropterin	-	All preparations”; dan					

(viii) dalam senarai “Vitamins; the following:”, dengan memotong butir-butir “Cholecalciferol”; dan

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai “**Antihistamines:**”, dengan memasukkan selepas butir-butir “Doxylamine” butir-butir “Ebastine”;

(ii) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—

(A) dengan memasukkan selepas butir-butir “Docetaxel” butir-butir “Durvalumab”; dan

(B) dengan memasukkan selepas butir-butir “Pomalidomide” butir-butir “Ponatinib”;

- (iii) dalam senarai “**Dermatological agents:**”, dengan memasukkan selepas butiran “Dithranol” butiran “Dupilumab”;
- (iv) dalam senarai “**Tranquillisers:**”, dengan memasukkan selepas butiran “Benzquinamide” butiran “Brexpiprazole”;  
dan
- (v) dalam senarai “**Miscellaneous:**”, dengan memasukkan selepas butiran “Sabadilla, alkaloids of” butiran “Sapropterin”.

Dibuat 25 Jun 2019  
[KKM.R.600-1/1/56 JLD.(4)(9); PN(PU2)172/XVII]

DATUK SERI DR. DZULKEFLY BIN AHMAD  
*Menteri Kesihatan*

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2019

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 2) Order 2019**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

*(a)* in the Poisons List—

- (i) in the list of “Antihistamines; the following:”, by inserting after the item “Doxylamine” the item “Ebastine”;
- (ii) by inserting after the item “Bretylum; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
"Brexiprazole	-	All preparations";					

(iii) by inserting after the item "Chlorzoxazone" and the particulars relating to it the following item:

<i>Name</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Cholecalciferol	-	All medicinal preparations containing 10,000 i.u. or more of cholecalciferol per dosage unit	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B or Group C";

(iv) by inserting after the item “Duloxetine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dupilumab	-	All preparations				
Durvalumab	-	All preparations”;				

(v) by substituting for the item “3,4-Methylenedioxy-methamphetamine (MDMA)(DD)” the item “3,4-Methylenedioxymethamphetamine (MDMA)(DD)”;

(vi) by inserting after the item “Pomalidomide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ponatinib	-	All preparations”;				

(vii) by inserting after the item “Santonin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sapropterin	-	All preparations”; and				

(viii) in the list of “Vitamins; the following:”, by deleting the item “Cholecalciferol”; and

(b) in the Appendix to the Poisons List—

(i) in the list of “**Antihistamines:**”, by inserting after the item “Doxylamine” the item “Ebastine”;

(ii) in the list of “**Antineoplastic agents and Immunosuppressants:**”—

(A) by inserting after the item “Docetaxel” the item “Durvalumab”; and

(B) by inserting after the item “Pomalidomide” the item “Ponatinib”;

(iii) in the list of “**Dermatological agents:**”, by inserting after the item “Dithranol” the item “Dupilumab”;

- (iv) in the list of “**Tranquillisers:**”, by inserting after the item “Benzquinamide” the item “Brexiprazole”; and
- (v) in the list of “**Miscellaneous:**”, by inserting after the item “Sabadilla, alkaloids of” the item “Sapropterin”.

Made 25 June 2019

[KKM.R.600-1/1/56 JLD.(4)(9); PN(PU2)172/XVII]

DATUK SERI DR. DZULKEFLY BIN AHMAD  
*Minister of Health*